Related Experiment Videos
Bridging phase 2 and phase 3 pneumococcal immunologic data for future combination vaccines
Insights
Pneumococcal conjugate vaccines (PncCs) are being introduced into childhood immunization schedules. Further research is needed to understand immune responses to PncC components and establish protective correlates.
Area of Science:
- Vaccinology
- Immunology
- Pediatric Public Health
Background:
- Pneumococcal conjugate vaccines (PncCs) are increasingly integrated into routine childhood immunization programs.
- Current PncCs are combination vaccines with multiple valents, posing challenges for evaluating individual component immunogenicity.
- Approval of next-generation PncCs and combination vaccines relies on immunogenicity and safety data.
Purpose of the Study:
- To review the current understanding of immune responses to pneumococcal conjugate vaccines (PncCs).
- To highlight the need for further investigation into factors influencing PncC immunogenicity and protective correlates.
- To inform future vaccine development and policy regarding PncCs.
Main Methods:
- Review of existing literature on pneumococcal conjugate vaccine immunogenicity and safety.
- Analysis of factors potentially affecting immune responses, including vaccine composition and co-administration with other vaccines.
- Discussion of antibody quantity and quality as measures of immune response.
Main Results:
- Immune responses to different PncC components can vary significantly.
- Population-based differences in immune responses to PncCs have been observed.
- The influence of concurrent vaccinations and genetic background on PncC immune response requires further study.
Conclusions:
- Robust data on minimal protective immune response and serologic correlates of protection for PncCs are still lacking.
- Further research is essential to define protective immune thresholds and optimize PncC utilization in public health.
- Understanding variability in immune responses is crucial for the successful implementation of next-generation PncCs.
Abstract:
Pneumococcal conjugate vaccines (PncCs) will be introduced into childhood vaccination programs now that the first PncC has been licensed for use. The next generation of PncCs and possible combination vaccines containing PncC will most probably be approved on the basis of phase 2 immunogenicity and safety data. PncCs are combination vaccines that include, at present, 7-11 components. Immune response to different components may vary. Furthermore, there seem to be population-based differences in immune response. Whether these differences are due to the other vaccines that are given simultaneously or due to the genetic background remains to be seen. Immune response can be evaluated by determining both the quantity and the quality of antibodies after vaccination. However, data are still missing on the minimal protective immune response and serologic correlates or surrogates of protection.